Multianalyte Test Predicts Drug Resistance in Esophageal Cancer
|
By LabMedica International staff writers Posted on 16 Mar 2015 |
|
Image: Histopathology of esophageal carcinoma showing infiltrating nests of neoplastic cells (Photo courtesy of Dr. Elliot Weisenberg, MD).
A multianalyte algorithmic immunohistochemistry (IHC) assay accurately identifies patients with locoregional esophageal adenocarcinoma (EC) who exhibit extreme resistance to neoadjuvant chemoradiotherapy.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Portable POCT Blood Gas Analyzer
BD100
Latest Pathology News
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more
New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Microbiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Technology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Industry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
